🔗 Share this article

Elected officials have raised concerns that the United Kingdom's series of deals with the US administration are "lacking a solid foundation." This stems from revelations that a much-touted deal on drug pricing, which pledges zero tariffs in exchange for the NHS increasing its costs, lacks any detailed agreement beyond limited headline terms contained within government press releases.

An Agreement in Principle Only

The arrangement concerning medicines, promoted as a "generational" achievement, exists as an "statement of intent" without formal ratification. Observers point out that the public statements from the UK and US governments frame the deal in sharply different terms. The British version focuses on securing "duty-free access" as a unique achievement, while the American announcement highlights the expectation for the NHS to pay 25% more for new medications.

"There is a serious risk that the UK government has made commitments to increase medicine costs in return for little more than a assurance from President Trump," stated David Henig, a trade expert. "We know he has form for not keeping promises."

Wider Concerns Amidst a Suspended Agreement

Worries have been amplified by Washington's move to pause the high-value digital accord, which was previously described as "a generational step-change" in the bilateral relationship. The US claimed a lack of progress from the UK on addressing wider trade issues as the reason for the pause.

In a separate development, concessions secured for British farmers as part of an May trade agreement have still not been formally signed off by the US, despite a imminent January deadline. "It is our belief that the US has failed to approve the agreed beef export quotas," said Tom Bradshaw of the National Farmers' Union.

Uncertainty Among Officials

In confidential discussions, ministers have admitted unease that the government's deals with Washington are unstable and unpredictable. One minister reportedly said the series of agreements as "built on sand," while another framed the situation as the "new normal" in the transatlantic relationship, marked by "additional layers of volatility and unpredictability."

Layla Moran, chair of the health select committee, remarked: "What is even more astonishing than the US approach is the UK government's naive belief that his administration is a good faith actor. The NHS is not a bargaining chip."

Official Reassurances and Concrete Outcomes

Government figures have attempted to minimize the chances of the US backing out of the pharmaceuticals deal. One source suggested the US pharmaceutical industry itself had been pushing for the agreement, seeking certainty on imports and pricing, making it less abstract than the paused tech deal.

Officials acknowledge that volatility is a feature of dealing with the Trump administration. However, they argue that the UK has obtained tangible results for businesses, such as lower steel tariffs compared to other nations. "The fact we have 25% steel tariffs, which is better than the rate for the rest of the world, is not flimsy," one official said.

However, delays have surfaced in carrying out the initial US-UK accord. Promised reciprocal agricultural allowances have yet to be finalized, and the commitment to "reduce steel tariffs to zero" has is still pending, with tariffs fixed at 25%.

Moving forward, the two sides have scheduled to restart talks on the suspended digital agreement in January, following what were described as "productive" meetings between UK and US officials in Washington.